Skip to main navigation Skip to search Skip to main content

Association between Group B Streptococcus and Clinical Chorioamnionitis by Gestational Week at Delivery—A Multicenter Cohort Study

  • Jennifer A. McCoy*
  • , Tzuria Peled
  • , Ari Weiss
  • , Lisa D. Levine
  • , Sorina Grisaru-Granovsky
  • , Misgav Rottenstreich
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective In the era of group B Streptococcus (GBS) screening and intrapartum antibiotic prophylaxis (IAP), GBS colonization has been associated with a lower risk of chorioamnionitis, possibly due to a protective effect of IAP. We sought to confirm this finding and assess whether this association varies by gestational week at delivery. Study Design We performed a retrospective cohort study of term (37.0–42.6 weeks), singleton parturients with known GBS status who delivered from 2005 to 2021 at two academic medical centers in Israel. We excluded patients who underwent planned cesarean, out of hospital birth, or had a fetal demise. Patients received GBS screening and IAP for GBS positivity as routine clinical care. The primary outcome was a diagnosis of clinical chorioamnionitis as determined by the International Classification of Diseases 10th Revision code, compared between GBS-positive and -negative groups, and assessed by gestational week at delivery. Results Of 292,126 deliveries, 155,255 met inclusion criteria. In total, 30.1% were GBS positive and 69.9% were negative. GBS-positive patients were 21% less likely to be diagnosed with clinical chorioamnionitis than GBS-negative patients, even after controlling for confounders (1.5 vs. 2.2%, adjusted odds ratio: 0.79, 95% confidence interval: 0.68–0.92). When assessed by gestational week at delivery, there was a significantly greater difference in rates of clinical chorioamnionitis between GBS-positive versus GBS-negative groups with advancing gestational age: 1.5-fold difference at 38 to 40 weeks, but a twofold difference at 42 weeks. The risk of clinical chorioamnionitis remained stable in the GBS-positive group, but increased significantly in the GBS-negative group at 41- and 42-week gestation (2.0 vs. 2.9%, p < 0.01 at 41 weeks; up to 3.9% at 42 weeks, p < 0.01). Conclusion In a large multicenter cohort with universal GBS screening and IAP, GBS positivity was associated with a lower risk of chorioamnionitis, driven by an increasing rate of chorioamnionitis among GBS-negative patients after 40 weeks.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalAmerican Journal of Perinatology
Volume42
Issue number2
DOIs
StatePublished - 21 Jun 2024

Bibliographical note

Publisher Copyright:
© 2024. Thieme. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • GBS
  • antibiotics
  • chorioamnionitis
  • group B Streptococcus
  • pathogenic bacterium

Fingerprint

Dive into the research topics of 'Association between Group B Streptococcus and Clinical Chorioamnionitis by Gestational Week at Delivery—A Multicenter Cohort Study'. Together they form a unique fingerprint.

Cite this